The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!

Athyros, Vasilios G.; Katsiki, Niki; Karagiannis, Asterios; Mikhailidis, Dimitri P.

doi:10.1185/03007995.2014.924488

Cited by 10 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study included subjects who were referred for the management of documented hyperlipidemia and did not address statin treatment eligibility. Nevertheless, a significant proportion of subjects at very high risk may be missed or undertreated by applying the ASCVD risk algorithm proposed by the ACC/ AHA 25,26 . Specifically, individuals with chronic kidney disease, carotid stenosis, abdominal aortic aneurysm or with diabetes and aged 540 or 475 years would be mistreated; those having ASCVD risk !7.5% would probably be undertreated since they would not be candidates for high-intensity statin therapy; or those having ASCVD risk 57.5% (SCORE 52.5%) would not be eligible for taking a statin.…”

Section: Discussionmentioning

confidence: 99%

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

Barkas

Milionis

Kostapanos

et al. 2014

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

Barkas

Milionis

Kostapanos

et al. 2014

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

show abstract

“…With respect to several patient groups, the ACC/AHA paper largely accords with the current European guidelines [ 8 ], yet the equations underlying risk assessment have not been sufficiently validated and agreed upon for European collectives. For this reason, the EAS [ 103 ] and other societies including the “D•A•CH-Gesellschaft Prävention von Herz-Kreislauf-Erkrankungen”, the AAS, and the Swiss Society of Cardiology [ 104 ] reject the positions formulated in the ACC/AHA paper.…”

Section: Statement On the 2013 Acc/aha Consensusmentioning

confidence: 99%

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications

Toplak

Ludvik

Lechleitner³

et al. 2016

Wien Klin Wochenschr

View full text Add to dashboard Cite

SummaryIn 2010, eight Austrian medical societies proposed a joint position statement on the management of metabolic lipid disorders for the prevention of vascular complications. An updated and extended version of these recommendations according to the current literature is presented, referring to the primary and secondary prevention of vascular complications in adults, taking into consideration the guidelines of other societies. The “Austrian Lipid Consensus – 2016 update” provides guidance for individualized risk stratification and respective therapeutic targets, and discusses the evidence for reducing vascular endpoints with available lipid-lowering therapies. Furthermore, specific management in key patient groups is outlined, including subjects presenting with coronary, cerebrovascular, and/or peripheral atherosclerosis; diabetes mellitus and/or metabolic syndrome; nephropathy; and familial hypercholesterolemia.

show abstract

“…The approach to the patient's CVD risk according to a specific LDL-c target has been adopted by most scientific societies. On the contrary, the American College of Cardiology/American Heart Association (ACC/ AHA) guidelines propose a ≥50% reduction in LDL-c in high CVD risk patients (recommending high-intensity statin therapy) or a 30-50% reduction in LDL-c in those with moderate CVD risk (recommending moderate-intensity statins) [4]. This approach could significantly expand the number of patients receiving statins if implemented in the European population (nearly all men and two-thirds of women older than 65 years) [5].…”

Section: Introductionmentioning

confidence: 99%

“…This approach could significantly expand the number of patients receiving statins if implemented in the European population (nearly all men and two-thirds of women older than 65 years) [5]. It also leads to suboptimal treatment of patients in specific categories, such as those with FH [4].…”

Section: Introductionmentioning

confidence: 99%

Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?

et al. 2018

Self Cite

View full text Add to dashboard Cite

Specific dietary strategies are the mainstay of management in most cases of dyslipidaemia, prior to or simultaneously with the initiation of a lipid-lowering agent. The exact approach differs according to the type of dyslipidaemia. In particular, a reduction in carbohydrates (mainly foods with a high glycaemic index) and their substitution with mono- and polyunsaturated fatty acids is the main strategy in patients with high levels of triglycerides (Tg) and/or low levels of high-density lipoprotein cholesterol (HDL-c). A reduction in saturated and trans fatty acids, combined with an increased intake of specific dietary components, such as plant sterols, soy protein and red yeast rice, constitutes the more efficacious dietary approach in cases where levels of total cholesterol and low-density lipoprotein cholesterol (LDL-c) are elevated. A reduction in excessive body weight is beneficial in every type of dyslipidaemia, whereas increased physical activity is mostly effective in cases with low HDL-c and high Tg levels. With respect to the potential cardiovascular benefit of these dietary interventions, there is currently evidence for the Mediterranean diet. Potential benefit may derive also from single dietary components of that diet, such as legumes, fruits, vegetables, nuts and omega-3 fatty acids, although to a lesser extent than with that general dietary pattern. The purpose of this review is to outline current knowledge regarding the recommended specific dietary pattern according to the type of dyslipidaemia and the evidence for the potential cardiovascular benefits of such approaches.

show abstract

The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!

Cited by 10 publications

References 35 publications

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications

Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?

Contact Info

Product

Resources

About